Christopher Anzalone
Vermogen: 321 M $ op 31-07-2026
Vermogen: 321 M $ op 31-07-2026
Christopher Richard Anzalone is een zakenman die Benet Group LLC en Nanotope, Inc. heeft opgericht en aan het hoofd heeft gestaan van 5 verschillende bedrijven. Momenteel is hij President, Chief Executive Officer & Director bij Arrowhead Pharmaceuticals, Inc. en Voorzitter & Chief Executive Officer van Calando Pharmaceuticals, Inc. (een dochteronderneming van Arrowhead Pharmaceuticals, Inc.). Dr. Anzalone zit ook in de raad van bestuur van 5 andere bedrijven. In zijn vorige carrière was Dr. Anzalone Chief Executive Officer bij NanoInk, Inc., Partner bij Galway Partners LLC, President, Chief Executive Officer & Director bij Nanotope, Inc. en Chief Executive Officer bij Benet Group LLC. Christopher Richard Anzalone behaalde een doctoraat aan de University of California, Los Angeles en een doctoraat aan de Lawrence University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-01-2026 | 3.792.739 ( 2,69% ) | 321 M $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Algemeen Directeur | 01-12-2007 |
Ablaris Therapeutics, Inc. | Directeur/Bestuurslid | - |
Tego Biosciences Corp. | Directeur/Bestuurslid | - |
Arrowhead Madison, Inc. | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing Manufactures nanolithography tools and other nanoscale devices | President | 01-01-2004 |
Galway Partners LLC
Galway Partners LLC Investment ManagersFinance Acts as an alternative investment manager | Corporate Officer/Principal | 01-01-2003 |
| KRONOS BIO, INC. | Directeur/Bestuurslid | - |
| VIR BIOTECHNOLOGY, INC. | Directeur/Bestuurslid | - |
Roche Madison, Inc.
Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Provides gene transfer technologies to the pharmaceutical industry | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 15 |
|---|---|
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drugs to treat intractable diseases | Health Technology |
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing Manufactures nanolithography tools and other nanoscale devices | Producer Manufacturing |
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in the design and development of drug-delivery-enhanced small molecule therapeutics | Health Technology |
Nanotope, Inc.
Nanotope, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lawrence University
Lawrence University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Madison, Inc.
Roche Madison, Inc. Pharmaceuticals: MajorHealth Technology Provides gene transfer technologies to the pharmaceutical industry | Health Technology |
Unidym, Inc.
Unidym, Inc. Electronic Production EquipmentElectronic Technology Develops and manufactures carbon nanotubes | Electronic Technology |
Benet Group LLC
Benet Group LLC Financial ConglomeratesFinance Private equity firm | Finance |
Galway Partners LLC
Galway Partners LLC Investment ManagersFinance Acts as an alternative investment manager | Finance |
Ablaris Therapeutics, Inc. | |
Tego Biosciences Corp. | |
Arrowhead Madison, Inc. | |
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Kronos Bio, Inc.
Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau